Hopes to combat dyskinesia as Parkinson's UK and Michael J Fox Foundation join forces
A brand new trial is underway to trial a drug which may combat dyskinesia in people with Parkinson's.
The phase 2 study is being funded by a partnership across Parkinson's UK and the Michael J Fox Foundation in the USA to test a new drug, NLX-112, in people with Parkinson's.
NLX-112 works by targeting serotonin producing brain cells which are believed to contribute to the development of dyskinesia, a commonly experienced side effect in those with Parkinson's who have been taking levodopa-based medication for several years.
The biopharma company Neurolixis will lead the study and will assess safety and tolerance of NLX-112 as well as its impact on reducing dyskinesia and some non-motor symptoms including mood and sleep problems.
'The things you can't get from the books'
Parkinson's Academy, our original and longest running Academy, houses 20 years of inspirational projects, resources, and evidence for improving outcomes for people with Parkinson's. Led by co-founder and educational director Dr Peter Fletcher, the Academy has a truly collegiate feel and prides itself on delivering 'the things you can't get from books' - a practical learning model which inspires all Neurology Academy courses.